Oral squamous cell carcinoma (SCC) is characterized by a high degree of local invasiveness and a high rate of metastasis to cervical lymph nodes, but a low rate of metastasis to distant organs.[1](#ijc31811-bib-0001){ref-type="ref"}, [2](#ijc31811-bib-0002){ref-type="ref"} Several investigators have attempted to identify the factors associated with biological aggressiveness of oral SCC.[3](#ijc31811-bib-0003){ref-type="ref"}, [4](#ijc31811-bib-0004){ref-type="ref"} Many oncogene products,[5](#ijc31811-bib-0005){ref-type="ref"}, [6](#ijc31811-bib-0006){ref-type="ref"}, [7](#ijc31811-bib-0007){ref-type="ref"}, [8](#ijc31811-bib-0008){ref-type="ref"}, [9](#ijc31811-bib-0009){ref-type="ref"} mutated tumor suppressor gene products,[10](#ijc31811-bib-0010){ref-type="ref"}, [11](#ijc31811-bib-0011){ref-type="ref"}, [12](#ijc31811-bib-0012){ref-type="ref"} cell adhesion molecules,[13](#ijc31811-bib-0013){ref-type="ref"}, [14](#ijc31811-bib-0014){ref-type="ref"}, [15](#ijc31811-bib-0015){ref-type="ref"} matrix metalloproteinases[16](#ijc31811-bib-0016){ref-type="ref"}, [17](#ijc31811-bib-0017){ref-type="ref"}, [18](#ijc31811-bib-0018){ref-type="ref"} and cell cycle‐associated molecules[19](#ijc31811-bib-0019){ref-type="ref"}, [20](#ijc31811-bib-0020){ref-type="ref"}, [21](#ijc31811-bib-0021){ref-type="ref"} have been proposed as possible factors controlling the biological behavior of oral SCC. However, no distinct factors controlling the aggressiveness of oral SCC have been identified to date. In addition, although several pathologists have attempted to identify the histological characteristics of oral SCC with metastatic potential,[22](#ijc31811-bib-0022){ref-type="ref"} it is difficult to predict the metastatic potential of oral SCC from its histopathological features alone. At present, therefore, the biological aggressiveness of oral SCC cannot be predicted from its superficial phenotype or the morphology of the cancer cells. It is necessary to examine the fundamental properties of the cancer cells, either determining their origin or examining stem cells, to predict biological aggressiveness.

Almost 30 years ago, we established the cell line, TYS, from well‐differentiated SCC of the oral floor.[23](#ijc31811-bib-0023){ref-type="ref"} Interestingly, TYS cells exhibited a high level of carcinoembryonic antigen expression, which is a known tumor marker for adenocarcinoma, and the cells formed adenosquamous cell carcinoma in nude mice. Moreover, we reported that HSG cells, which were established from the irradiated submandibular gland,[24](#ijc31811-bib-0024){ref-type="ref"} formed adenocarcinoma in nude mice and could differentiate into several different cell types on treatment with different differentiation inducers.[25](#ijc31811-bib-0025){ref-type="ref"}, [26](#ijc31811-bib-0026){ref-type="ref"} During these experiments, we found that HSG‐derived cells differentiated into keratinizing SCC on treatment with retinoic acid.[27](#ijc31811-bib-0027){ref-type="ref"} These experiments suggest that some population of salivary gland cells may be parental cells to SCC in the oral cavity.

Based on the results of our previous basic research,[23](#ijc31811-bib-0023){ref-type="ref"}, [24](#ijc31811-bib-0024){ref-type="ref"}, [25](#ijc31811-bib-0025){ref-type="ref"}, [26](#ijc31811-bib-0026){ref-type="ref"}, [27](#ijc31811-bib-0027){ref-type="ref"} we hypothesized that some oral SCCs may originate from minor salivary glands. Thus, oral SCC may consist of two different cancers: SCC derived from squamous epithelium (mucosal‐SCC) and SCC derived from minor salivary glands (salivary‐SCC). Salivary gland cancer is generally more resistant to radiation therapy and chemotherapy, metastasizes frequently to lymph nodes and distant organs and shows poor prognosis compared to mucosal‐SCC.[28](#ijc31811-bib-0028){ref-type="ref"} Therefore, it is important to know the origin of SCC of the oral cavity to provide appropriate treatment.

In our study, we attempted to discriminate salivary‐SCC from mucosal‐SCC of the oral floor by microarray and clustering analyses, and identified nine molecular markers that allow us to identify salivary‐SCC in oral SCC. Furthermore, we compared the biological aggressiveness and prognosis of salivary‐SCC and mucosal‐SCC, and clarified that salivary‐SCC showed more aggressive biological behavior and poorer prognosis than mucosal‐SCC.

Material and Methods {#ijc31811-sec-0002}
====================

Patients {#ijc31811-sec-0003}
--------

Samples from six patients with SCC of the oral floor (five men, one woman) were subjected to microarray analysis (Fig. [1](#ijc31811-fig-0001){ref-type="fig"} *a*, Table [1](#ijc31811-tbl-0001){ref-type="table"}). Histopathological diagnoses were made by experienced pathologists in our hospital; all were diagnosed as SCC (Fig. [1](#ijc31811-fig-0001){ref-type="fig"} *b*). The mode of cancer cell invasion was assessed using the Yamamoto--Kohama (Y‐K) mode of invasion classification for oral SCC[22](#ijc31811-bib-0022){ref-type="ref"}; most of the cancers used for microarray analysis were advanced (Stage III or Stage IVa) and highly invasive (Y‐K3 or Y‐K4D).

![Clinical and histopathological appearances, and clustering analysis of six SCCs of the oral floor. (*a*) Clinical appearance of the SCCs subjected to microarray analysis. There were no clear differences in clinical appearance between the six SCCs of the oral floor. (*b*) Histopathological appearance of the SCCs subjected to microarray analysis. There were no clear differences in histopathological appearance between the six SCCs of the oral floor.](IJC-143-2551-g001){#ijc31811-fig-0001}

###### 

Clinical and histopathological characteristics of six cases of SCC of the oral floor

  Case     Gender    Age, years  Histology   TNM classification   Y‐K mode of invasion
  -------- -------- ------------ ----------- -------------------- ----------------------
  Case 1   M             56      SCC         T3N2cM0              3
  Case 2   F             58      SCC         T2N1M0               3
  Case 3   M             60      SCC         T4N0M0               4D
  Case 4   M             60      SCC         T2N1M0               3
  Case 5   M             74      SCC         T4N2aM0              3
  Case 6   M             68      SCC         T4N2cM0              3

Samples from these six patients were subjected to microarray analysis

Samples from 66 patients with oral SCC (39 men, 27 women) were subjected to expression analysis by reverse transcription‐polymerase chain reaction (RT‐PCR). Each tumor had been surgically resected at our hospital between 1998 and 2009. The patients had not received any previous radiation therapy or chemotherapy. Gender, age, primary site, TN classification, clinical stage, tumor cell differentiation (WHO classification),[29](#ijc31811-bib-0029){ref-type="ref"} Anneroth\'s grade,[30](#ijc31811-bib-0030){ref-type="ref"} Y‐K mode of invasion[22](#ijc31811-bib-0022){ref-type="ref"} and pathological lymph node metastasis of the oral SCCs are shown in Table [2](#ijc31811-tbl-0002){ref-type="table"}. Tissue samples from the patients were fixed in formalin and embedded in paraffin, and sections 0‐μm thick were stained with hematoxylin and eosin for histopathological diagnosis.

###### 

Clinicopathological differences between salivary‐SCC and mucosal‐SCCs

  Characteristic                              Mucosal SCC (*n* = 54)   Salivary SCC (*n* = 12)   *p*‐value[1](#ijc31811-note-0003){ref-type="fn"}
  ------------------------------------------- ------------------------ ------------------------- --------------------------------------------------
  Gender no.(%)                                                                                  
  Female                                      24 (44.4)                3 (25.0)                  0.181
  Male                                        30 (55.6)                9 (75.0)                  
  Age no (%)                                                                                     
  \<60 years                                  21 (38.8)                0 (0.0)                   0.03
  60--69 years                                9 (16.7)                 5 (41.7)                  
  70--79 years                                18 (33.4)                4 (33.3)                  
  \>80 years                                  6 (11.1)                 3 (25.0)                  
  Primary site no (%)                                                                            
  Tongue                                      29 (53.7)                5 (41.8)                  0.831
  Upper gingiva                               8 (14.8)                 4 (33.3)                  
  Lower gingiva                               5 (9.3)                  1 (8.3)                   
  Oral floor                                  4 (7.4)                  1 (8.3)                   
  Buccal mucosa                               5 (9.3)                  1 (8.3)                   
  Palate                                      2 (3.7)                  0 (0.0)                   
  Lower lip                                   1 (1.8)                  0 (0.0)                   
  UICC T stage no (%)                                                                            
  T1                                          6 (11.1)                 0 (0.0)                   0.245
  T2                                          26 (48.1)                7 (58.3)                  
  T3                                          8 (14.8)                 0 (0.0)                   
  T4                                          14 (26.0)                5 (41.7)                  
  UICC N stage no (%)                                                                            
  N0                                          34 (63.0)                5 (41.7)                  0.327
  N1                                          11 (20.3)                3 (25.0)                  
  N2                                          9 (16.7)                 4 (33.3)                  
  UICC clinical stage no (%)                                                                     
  I                                           6 (11.1)                 0 (0.0)                   0.635
  II                                          19 (35.2)                5 (41.7)                  
  III                                         11 (20.4)                2 (16.6)                  
  IV                                          18 (33.3)                5 (41.7)                  
  Tumor cell differentiation no (%)                                                              
  High                                        32 (59.3)                2 (16.7)                  0.025
  Moderate                                    17 (31.5)                7 (58.3)                  
  Low                                         5 (9.2)                  3 (25.0)                  
  Anneroth\'s grade no (%)                                                                       
  I                                           1 (1.8)                  0 (0.0)                   0.172
  II                                          22 (40.7)                1 (8.3)                   
  III                                         23 (42.7)                8 (66.7)                  
  IV                                          8 (14.8)                 3 (25.0)                  
  Y‐K mode of invasion no (%)                                                                    
  1                                           8 (14.8)                 1 (8.3)                   0.544
  2                                           10 (18.5)                2 (16.7)                  
  3                                           20 (37.0)                4 (33.3)                  
  4C                                          14 (26.0)                3 (25.0)                  
  4D                                          2 (3.7)                  2 (16.7)                  
  Pathological lymph node metastasis no (%)                                                      
  Negative                                    43 (79.6)                6 (50.0)                  0.044
  Positive                                    11 (20.4)                6 (50.0)                  

Using the Chi‐squared test or Fisher\'s exact test.

Cell lines {#ijc31811-sec-0004}
----------

The human oral SCC cell lines, OSC‐20 and HSC‐4, were obtained from the Department of Oral and Maxillofacial Surgery, Kanazawa University, School of Medicine.[31](#ijc31811-bib-0031){ref-type="ref"}, [32](#ijc31811-bib-0032){ref-type="ref"} TYS cells are human oral adenosquamous carcinoma cells previously established by our research group.[23](#ijc31811-bib-0023){ref-type="ref"} OSC‐20, HSC‐4 and TYS cells were cultured in complete media consisting of Dulbecco\'s modified Eagle\'s medium (DMEM: Nissui, Tokyo, Japan) supplemented with 10% fetal bovine serum (FBS: Eqitech Bio, Kerrville, TX), 100 μg/mL streptomycin, 100 U/mL penicillin (Meiji Seika, Tokyo, Japan) and 0.25 μg/mL amphotericin B (Sigma‐Aldrich, St. Louis, MO) in a humidified atmosphere of 95% air and 5% CO~2~ at 37°C.

To confirm the origin and identity of the cells used in this experiment, we performed short tandem repeat (STR) analysis using 10 loci (Supporting Information Table [S1](#ijc31811-supitem-0003){ref-type="supplementary-material"}). As all of the cell lines used showed clear peaks with primers for human cells, these cells could be considered as being of human and not rodent origin. Furthermore, as the evaluation values (EV) among these cells were \<0.7, they could be considered as independent cells (Supporting Information Table [S2](#ijc31811-supitem-0003){ref-type="supplementary-material"}). The numbers of peaks in each allele from marker loci of HSC‐4 cells used in this experiment (Supporting Information Table [S1](#ijc31811-supitem-0003){ref-type="supplementary-material"}) were consistent with those reported in RIKEN BRC CELL BANK. On the other hand, STR analysis for OSC‐20 cells and TYS cells were not reported in any database. However, we confirmed that the numbers of peaks in each allele from the marker loci of OSC‐20 cells and TYS cells used in this experiment (Supporting Information Table [S1](#ijc31811-supitem-0003){ref-type="supplementary-material"}) were not consistent with those of widely used SCC cells, such as HeLa and A431.

RNA extraction {#ijc31811-sec-0005}
--------------

All cancer tissues were snap‐frozen and subjected to molecular analysis. Total RNA from the cell lines and tissues was extracted using a modified acid guanidinium--isothiocyanate--phenol--chloroform method with ISOGEN RNA extraction mixture (Nippon Gene, Tokyo, Japan) according to the manufacturer\'s recommendations. Tissue was resected from the central part of the tumors without necrosis; half was used for RNA preparation and half for histopathological diagnosis. The samples were confirmed to contain active cancer cells without any contamination of the minor salivary glands. The integrity of the RNA was confirmed by visualizing intact 28S and 18S rRNAs on 1% agarose gels.

Microarray analysis {#ijc31811-sec-0006}
-------------------

Total RNA was extracted by lysing the tissues using ISOGEN (Nippon Gene), following the manufacturer\'s instructions, and homogenizing them in 0.5 mL of ISOGEN using Tissue Lyser (Qiagen, Valencia, CA). The integrity of the RNA was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).

An Applied Biosystems Chemiluminescent RT‐IVT Labeling Kit (Life Technologies, Carlsbad, CA) was used to convert total RNA to digoxigenin (DIG)‐labeled cRNA. Double‐stranded cDNA was generated from 1 μg of total RNA, transcribed using DIG‐labeled nucleotides (Roche Diagnostics, Basel, Switzerland), fragmented and hybridized to a Human Genome Survey Array containing 32,878 probes (Life Technologies) according to the manufacturer\'s instructions. After washing each array, the signal was developed using a chemiluminescent detection kit (Life Technologies). Processed arrays were scanned with a 1700 chemiluminescent microarray analyzer (Life Technologies) and the results were analyzed using GeneSpring GX 13.0 (Agilent Technologies). Fold change analysis was conducted to identify probes with \>5‐fold differences, followed by moderated *t* test, *p*‐value computation (asymptotic) and multiple testing correction (Benjamini Hochberg FDR). The raw microarray data have been deposited in the Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.-gov/geo>, experiment number: GSE36090 and GSE70604), according to the minimum information about microarray experiment (MIAME) guidelines.

Reverse transcription‐polymerase chain reaction {#ijc31811-sec-0007}
-----------------------------------------------

cDNA was synthesized using random primers (Takara Bio, Shiga, Japan) and M‐MLV reverse transcriptase (Takara Bio) from 5 μg of total RNA. GAPDH and SCCA1 were amplified to confirm the quality of the cDNA. Subsequently, the products (1 μL) were subjected to PCR amplification under the appropriate conditions (annealing temperature, 60°C; and 25 or 30 amplification cycles) for each gene. PCR products were analyzed by agarose gel electrophoresis. The DNA was electrophoresed at 20 V for 20 min on 1.5% agarose gels, stained with 0.5 μg/mL ethidium bromide, and observed on a UV transilluminator.

Statistical analysis {#ijc31811-sec-0008}
--------------------

Statistical analysis was carried out using SPSS software (SPSS Inc., Chicago, IL). The Chi‐square test, Fisher\'s exact test (two‐tailed), univariate analysis and multivariate analysis with Cox regression model, and univariate Kaplan--Meier analysis were used for statistical analysis.

Ethical standards {#ijc31811-sec-0009}
-----------------

The Ethics Committee of Dokkyo Medical University School of Medicine approved this study. All patients gave their informed consent prior to inclusion in this study.

Results {#ijc31811-sec-0010}
=======

Identification of genes overexpressed in normal salivary glands {#ijc31811-sec-0011}
---------------------------------------------------------------

Using microarray analysis, we determined the gene expression profiles in five normal salivary glands and three normal oral squamous epithelium samples (GEO, <http://www.ncbi.nlm.nih.-gov/geo>, experiment number: GSE36090). A total of 845 probes showed overexpressed‐signals in the salivary glands as showing a change of \>5‐fold difference compared to the oral squamous epithelium. The 845 probes were subsequently used for clustering analyses.

Clustering analysis {#ijc31811-sec-0012}
-------------------

Clustering analysis based on the signal strength detected by 845 probes revealed that six oral SCC cases could be divided into two groups. The expression profile of one group (Cases 1, 3, 4 and 6) was similar to that of the oral squamous epithelium, and that of the other group (Cases 2 and 5) was similar to that of normal salivary glands (Fig. [2](#ijc31811-fig-0002){ref-type="fig"} *a*). Furthermore, we identified 12 of the 845 probes that can easily determine the origin of SCC of the oral floor (Fig. [2](#ijc31811-fig-0002){ref-type="fig"} *b*).

![Clustering analysis. (*a*) The six samples were divided into two groups based on clustering analysis by the levels of gene expression detected by 845 probes. The expression profile of one group (Cases 1, 4, 3 and 6) was similar to that of normal oral squamous epithelium, and that of the other group (Cases 2 and 5) was similar to that of normal salivary glands. (*b*) We identified 12 of the 845 probes that could identify the origin of the SCC of the oral floor by clustering analysis.](IJC-143-2551-g002){#ijc31811-fig-0002}

We further conducted clustering analysis on 167 oral SCC samples from a public database (GEO, <http://www.ncbi.nlm.nih.-gov/geo>, experiment number: GSE30784). These samples could be clearly divided into mucosal‐SCC and salivary‐SCC (Supporting Information Fig. [S1A](#ijc31811-supitem-0001){ref-type="supplementary-material"}) using 845 probes, and also with 23 probes for 13 genes including the 12 probes mentioned above (Supporting Information Fig. [S1B](#ijc31811-supitem-0001){ref-type="supplementary-material"}). Different probes were produced for each exon of each gene to detect the expression of several splicing variants. Therefore, the expression patterns for each probe on each gene were different.

Characteristics of the identified marker genes {#ijc31811-sec-0013}
----------------------------------------------

The characteristics of the identified marker genes are listed in Table [3](#ijc31811-tbl-0003){ref-type="table"}. Probes 8 and 9 are different clones of the same gene, so 11 genes were identified as markers. Most of the identified genes are related to the function and structure of the salivary glands (Genes 1, 2, 4, 6, 7 and 10), and some of the genes are tumor‐related (Genes 3 and 5). Gene 8 was reported to be stem cell‐related, and gene 12 is related to the immune system. Gene 11 is currently not in any database. The mRNA length, structure of the genome and number of amino acids were also examined in several databases. Several mRNA variants were reported for the identified marker genes except Gene 1, and the number of exons and coded amino acids varied between the genes.

###### 

Characteristics of the identified marker genes

  Probes   Name of gene                                Length of mRNA (bp)                                  Structure of genome   No. amino acids
  -------- ------------------------------------------- ---------------------------------------------------- --------------------- -----------------
  1        *Prolactin‐induced protein*                 591                                                  4 exons               147
  2        *alpha‐2‐glucoprotein1, zinc‐binding*       1278, var[a](#ijc31811-note-0004){ref-type="fn"}     4 exons               299
  3        *FRY‐like (MLL fusion partner)*             11,706, var[a](#ijc31811-note-0004){ref-type="fn"}   64 exons              3014
  4        *Lactotransferrin*                          2593, var[a](#ijc31811-note-0004){ref-type="fn"}     18 exons              866
  5        *Deleted in malignant brain tumors 1*       5802, var[a](#ijc31811-note-0004){ref-type="fn"}     53 exons              1786
  6        *WAP four‐disulfide core domain 2*          570, var[a](#ijc31811-note-0004){ref-type="fn"}      4 exons               125
  7        *Mucin 7, salivary*                         2467, var[a](#ijc31811-note-0004){ref-type="fn"}     5 exons               378
  8, 9     *Prominin 1*                                3977, var[a](#ijc31811-note-0004){ref-type="fn"}     29 exons              866
  10       *Cholinergic receptor, muscarinic 3*        2757, var[a](#ijc31811-note-0004){ref-type="fn"}     5 exons               591
  11       *Unknown*                                   Unknown                                              Unknown               Unknown
  12       *Leukocyte Ig‐like receptor, subfamily B*   2971, var[a](#ijc31811-note-0004){ref-type="fn"}     16 exons              651

Several mRNA variants are reported.

Reverse transcriptase‐polymerase chain reaction {#ijc31811-sec-0014}
-----------------------------------------------

Upstream and downstream primers were designed based on the different exons to amplify the core domains of several mRNA variants (Supporting Information Table [S3](#ijc31811-supitem-0003){ref-type="supplementary-material"}). Primers for Gene 11 could not be designed because the structures of its mRNA and genome have not been reported. Primers for Gene 12 cannot be designed because of its high degree of identity with several other genes. Thus, we have nine marker genes for further experiments. The expected length of the PCR products and the cycles used are also listed in Supporting Information Table [S3](#ijc31811-supitem-0003){ref-type="supplementary-material"}. To determine the appropriate conditions for amplification, we used three well‐characterized cell lines, *i.e*., OSC‐20 and HSC‐4 as mucosal‐SCCs, and TYS as a salivary‐SCC. TYS cells expressed six of the nine markers, but OSC‐20 and HSC cells faintly expressed only one and two markers, respectively (Table [4](#ijc31811-tbl-0004){ref-type="table"}). Therefore, these nine marker genes can be used to discriminate salivary‐SCC from mucosal‐SCC.

###### 

Oral SCCs possibly originating from minor salivary glands

  Case no.   Primary site    Gene 1   Gene 2   Gene 3   Gene 4   Gene 5   Gene 6   Gene 7   Gene 8   Gene 10
  ---------- --------------- -------- -------- -------- -------- -------- -------- -------- -------- ---------
  1          upper gingiva   \+       \+       \+       −        −        −        −        +++      \+
  2          lower gingiva   ++       \+       −        \+       −        −        ++       ++       \+
  3          upper gingiva   \+       \+       −        \+       +++      −        +++      \+       −
  4          tongue          \+       \+       NE       \+       ++       NE       \+       \+       NE
  6          upper gingiva   \+       +++      +++      ++       ++       ++       +++      \+       +++
  7          tongue          \+       +++      +++      ++       NE       NE       NE       NE       NE
  15         buccal mucosa   −        +++      \+       −        −        \+       ++       \+       ++
  17         tongue          ++       \+       −        −        \+       \+       \+       ++       \+
  56         upper gingiva   \+       +++      −        −        ++       −        −        ++       \+
  64         oral floor      \+       \+       −        −        ++       \+       −        ++       \+
  68         upper gingiva   −        \+       −        +++      +++      −        ++       +++      −
  72         tongue          −        ++       −        −        −        \+       \+       +++      \+
                                                                                                     
  TYS        salivary‐SCC    +++      −        ++       −        ++       \+       ++       ++       −
  HSC        mucosal‐SCC     −        −        \+       −        −        −        \+       −        −
  OSC        mucosal‐SCC     −        −        \+       −        −        −        −        −        −

+++: very strongly positive, ++: strongly positive, +: positive, −: negative, NE: not examined.

Twelve cases from 66 oral SCC (18.2%) were considered to originate from minor salivary glands.

TYS (six positive per nine markers) is a known SCC cell line derived from the minor salivary gland. HSC cells (two faint positive in nine markers) and OSC cells (one faint positive in nine markers) are SCC cells derived from oral squamous epithelium.

Identification of the origin of oral SCC {#ijc31811-sec-0015}
----------------------------------------

We examined the expression levels of nine marker genes in samples of 66 oral SCCs by RT‐PCR and determined the origin of the SCC. Band intensity on RT‐PCR was judged as very strongly positive (+++), strongly positive (++), positive (+) or negative (−) (Table [4](#ijc31811-tbl-0004){ref-type="table"}). We considered 11 cases (Cases 1, 2, 3, 4, 6, 15, 17, 56, 64, 68 and 72) that expressed at least five marker genes to be salivary‐SCCs (Table [4](#ijc31811-tbl-0004){ref-type="table"}). Case 7, which strongly expressed four marker genes, was also considered to be salivary‐SCC (Table [4](#ijc31811-tbl-0004){ref-type="table"}). Thus, we identified 12 cases (18.2%) from 66 oral SCCs that could originate from minor salivary glands.

Clinicopathological differences between salivary‐SCC and mucosal‐SCCs {#ijc31811-sec-0016}
---------------------------------------------------------------------

We examined the clinicopathological differences between salivary‐SCC group and mucosal‐SCC group by the Chi‐squared test and Fisher\'s exact test (Table [2](#ijc31811-tbl-0002){ref-type="table"}). Although there was no significant difference in gender distribution between the groups, the salivary‐SCC group had more elderly patients than the mucosal‐SCC group (*p* = 0.031). There were also no significant differences in primary site, UICC T stage, UICC N stage or UICC clinical stage between the groups. However, there was a significant difference in tumor cell differentiation by WHO classification between the groups (*p* = 0.025). The salivary‐SCC group had more patients with low and moderate grade tumor cell differentiation than those with high grade. There was no significant difference in Anneroth\'s histopathological malignant grade or Y‐K mode of invasion between the groups. Interestingly, the salivary‐SCC group showed more pathological lymph node metastasis than the mucosal‐SCC group \[50.0% (6 cases/12 cases) *vs*. 20.4% (11 cases/54 cases), *p* = 0.044\].

Tumor‐related mortality by variable clinicopathological factors {#ijc31811-sec-0017}
---------------------------------------------------------------

Tumor‐related mortality (TRM) was analyzed by variable factors using univariate analysis with a Cox regression model (Table [5](#ijc31811-tbl-0005){ref-type="table"}). Although TRM was unaffected by gender, primary site, UICC N stage and UICC clinical stage, TRM was significantly increased by UICC T stage (*p* = 0.048) and age (\>80 years old) (*p* = 0.031). On the histopathological aspects, patients with low and moderate grade tumor cell differentiation showed higher TRM than patients with high grade of tumor cell differentiation. However, TRM were unaffected by Anneroth\'s grade, Y‐K mode of invasion and the presence of histological lymph node metastasis (Table [5](#ijc31811-tbl-0005){ref-type="table"}). Surprisingly, the salivary‐SCC group showed much higher TRM than the mucosal group (HR = 3.12, 95%CI, 1.15--8.49; *p* = 0.025).

###### 

Tumor‐related mortality by variable clinicopathological factors with Cox regression model

                               Univariate analysis   Multivariate analysis[a](#ijc31811-note-0008){ref-type="fn"}                                
  ---------------------------- --------------------- -------------------------------------------------------------- ------- ------ ------------- -------
  Gender                                                                                                                                         
  Female                       1.00                                                                                                              1.00
  Male                         0.95                  0.36--2.49                                                     0.910   0.73   0.244--2.18   0.572
  Age                                                                                                                                            
  \<60 years                   1.00                                                                                                              1.00
  60--69 years                 2.28                  0.51--10.21                                                    0.280   2.29   0.42--12.4    0.336
  70--79 years                 1.67                  0.40--6.98                                                     0.484   1.58   0.33--7.69    0.57
  \>80 years                   4.84                  1.15--20.33                                                    0.031   3.27   0.92--16.28   0.149
  Primary site                                                                                                                                   
  Tongue                       1.00                                                                                                              
  Upper gingiva                0.58                  0.13--2.68                                                     0.485                        
  Lower gingiva                1.47                  0.32--6.81                                                     0.622                        
  Oral floor                   2.55                  0.69--9.45                                                     0.161                        
  Buccal mucosa                0.62                  0.08--4.89                                                     0.649                        
  Palate                       NA                    NA                                                                     NA                   
  Lower lip                    NA                    NA                                                                     NA                   
  UICC T stage                                                                                                                                   
  T1--T3                       1.00                                                                                                              1.00
  T4                           2.62                  1.01--6.79                                                     0.048   2.67   0.92--7.7     0.07
  UICC N stage                                                                                                                                   
  N0                           1.00                                                                                                              
  N1                           2.66                  0.73--9.67                                                     0.138                        
  N2                           1.96                  0.61--6.25                                                     0.256                        
  UICC clinical stage                                                                                                                            
  I--III                       1.00                                                                                                              
  IV                           1.34                  0.51--3.52                                                     0.554                        
  Tumor cell differentiation                                                                                                                     
  High                         1.00                                                                                                              1.00
  Moderate                     3.52                  1.08--11.45                                                    0.036   2.69   0.75--9.72    0.130
  Low                          5.18                  1.29--20.71                                                    0.020   5.04   1.03--24.5    0.045
  Anneroth\'s grade                                                                                                                              
  I--III                       1.00                                                                                                              
  IV                           1.76                  0.57--5.39                                                     0.325                        
  Y‐K mode of invasion                                                                                                                           
  1                            1.00                                                                                                              
  2                            1.08                  0.18--6.48                                                     0.931                        
  3                            1.39                  0.29--6.72                                                     0.678                        
  4C                           1.11                  0.20--6.05                                                     0.906                        
  4D                           1.03                  0.09--11.38                                                    0.980                        
  Pathological                                                                                                                                   
  Lymph Node metastasis                                                                                                                          
  Negative                     1.00                                                                                                              
  Positive                     2.21                  0.84--5.81                                                     0.108                        
  Origin                                                                                                                                         
  Mucosal                      1.00                                                                                                              1.00
  Salivary                     3.12                  1.15--8.49                                                     0.025   1.28   0.36--4.48    0.705

Variables with *p* \< 0.05 on univariate analysis, excluding gender, were entered.

We further examined TRM on age, UICC T stage, tumor cell differentiation and tumor origin by multivariate analysis (Table [3](#ijc31811-tbl-0003){ref-type="table"}). Contrary to our expectation, only UICC T stage (T4) and tumor cell differentiation (low) showed higher TRM than the others.

Kaplan--Meier analysis {#ijc31811-sec-0018}
----------------------

Kaplan--Meier curves were drawn and the log‐rank test was used to investigate the correlation of Salivary‐SCC and Mucosal‐SCC with 5‐year event‐free survival (Fig. [3](#ijc31811-fig-0003){ref-type="fig"}).

![Kaplan--Meier analysis. Kaplan--Meier curve suggested that the salivary‐SCC group had poorer 5‐year event‐free survival compared to the mucosal‐SCC group (*p* = 0.017).](IJC-143-2551-g003){#ijc31811-fig-0003}

The Kaplan--Meier curve suggested that the salivary‐SCC group was associated with poorer 5‐year event‐free survival compared to the mucosal‐SCC group (*p* = 0.017).

Discussion {#ijc31811-sec-0019}
==========

The results of the present study clearly indicated that oral SCC has two different origins, mucosal‐SCC and salivary‐SCC, by clustering analysis of whole gene expression using our own six oral SCC cases as well as 167 oral SCC cases in the public database (GEO). At present, patients with oral SCC, either mucosal or salivary, are treated by the same protocol. Moreover, we and other researchers have treated the two cancers the same way when investigating the biological characteristics of oral SCC. In future, mucosal‐SCC should be treated as conventional SCC, and salivary‐SCC as salivary gland cancer.

Eighteen percent of oral SCC was considered to originate from the salivary glands in our cohort. Although there was no significant difference in gender distribution between the salivary‐SCC group and mucosal‐SCC group, the salivary‐SCC group had more elderly patients than the mucosal‐SCC group. There were also no significant differences in primary site, UICC T stage, UICC N stage or UICC clinical stage between the groups. The salivary‐SCC group had more patients with low and moderate grade tumor cell differentiation than those with high grade differentiation, but there were no significant differences in the other factors. These observations indicated that there was no phenotypic difference between groups. It was noteworthy that the salivary‐SCC group showed frequent metastasis to cervical lymph nodes compared to the mucosal‐SCC group. Furthermore, the origin of SCC as well as UICC T stage, tumor cell differentiation was significantly correlated with TRM by univariate analysis in our cohort. However, the origin of SCC was not extracted as an explanatory variable for TRM by multivariate analysis. Only tumor cell differentiation was extracted as an explanatory variable for TRM by multivariate analysis. Tumor cell differentiation may be strongly associated with the origin of SCC and affect the origin of SCC as a confounding factor on TRM. On the other hand, the 5‐year event‐free survival of the salivary‐SCC group was significantly lower than that of the mucosal‐SCC group on Kaplan--Meier analysis.

In this experiment, we performed semi‐quantitative RT‐PCR to detect the expression of marker genes in the clinical materials. We initially attempted to quantify the expression levels of these genes in oral SCC tissues using GAPDH as an RNA quality control and SCC1 as a control for the ratio of epithelial cells by TaqMan PCR. However, because the clinical oral SCC samples contained cancer cells in various levels and various activities and/or the expression levels of target genes and control genes were quite different, we could not obtain clear data from quantitative RT‐PCR. As the purpose of the RT‐PCR experiment was qualitative detection of the expression of marker genes, semi‐quantitative RT‐PCR, in which three cultured cells were used as internal controls under strict manipulation, was sufficient to confirm our hypothesis.

The primary sites of salivary‐SCC were the upper gingiva, lower gingiva, tongue, oral floor and buccal mucosa. There are many minor salivary glands in the oral floor and buccal mucosa, so it is possible to understand that tumors in this region may originate from minor salivary glands. However, this raises the question why salivary‐SCC occurs in the gingiva and tongue. Salivary‐SCC in the gingiva may occur in the non‐keratinized buccal gingiva, which contains many minor salivary glands in the submucosal area, and invade into the keratinized alveolar gingival area. Salivary‐SCC in the tongue may occur in the non‐keratinized ventral mucosa, which again contains many minor salivary glands or sublingual glands, and invade into the keratinized side edge or dorsal area of the tongue.

Salivary gland cancer is generally recognized as being more resistant to radiation therapy and chemotherapy than mucosal‐SCC---it frequently metastasizes to distant organs and shows poor prognosis.[33](#ijc31811-bib-0033){ref-type="ref"}, [34](#ijc31811-bib-0034){ref-type="ref"} Surgically, 10‐mm safety margins are recommended for resection of oral SCC,[35](#ijc31811-bib-0035){ref-type="ref"}, [36](#ijc31811-bib-0036){ref-type="ref"} while safety margins of \>20--25 mm are recommended for salivary gland cancer, such as adenoid cystic carcinoma.[37](#ijc31811-bib-0037){ref-type="ref"} Thus, salivary‐SCC should probably be treated as salivary gland cancer and resected with wide safety margins. Salivary‐SCC frequently metastasizes to cervical lymph nodes. Therefore, clinicians should be wary of enlarged cervical lymph nodes on CT or MRI for salivary‐SCC, and suspicious lymph nodes should be removed by neck dissection.

In our study, we could not compare chemosensitivity or radiosensitivity between mucosal‐SCC and salivary‐SCC because the numbers of cases were limited. Generally, salivary gland tumors show chemo‐ and/or radiation resistance compared to mucosal‐SCC.[28](#ijc31811-bib-0028){ref-type="ref"} Therefore, induction chemo‐radiation therapy may not be suitable for resistant salivary‐SCC and should not be chosen based on the histopathological diagnosis alone. If we choose induction chemo‐radiation therapy for salivary‐SCC, the tumor may progress to a higher stage or become inoperable after induction therapy.

To confirm the aims of this study, further large‐scale studies into the origin and biological aggressiveness of oral SCC are required. We are now working to establish a high‐throughput system to determine the origin of oral SCC, discriminating salivary‐SCC from mucosal‐SCC using immunohistochemical staining for nine markers combined with quantitative PCR. We preliminarily confirmed the expression of marker gene products in salivary‐SCC tissues (Supporting Information Figs. [S2A](#ijc31811-supitem-0003){ref-type="supplementary-material"} and [S2B](#ijc31811-supitem-0003){ref-type="supplementary-material"}). Furthermore, an interinstitutional collaborative study is underway to accumulate larger numbers of cases. Determination of the origin of oral SCC, whether mucosal or salivary, will be helpful in designing appropriate treatment plans for patients with oral SCC.

Supporting information
======================

###### 

**Figure S1**. Clustering analysis of 167 OSCC samples from the public database We further conducted clustering analysis on 167 OSCC samples from the public database (GEO, <http://www.ncbi.nlm.nih.-gov/geo>, experiment number: GSE30784). These samples could be clearly divided into mucosal‐SCC and salivary‐SCC by 845 probes (Fig. S1A) and also by 23 probes, including 12 probes (Fig. S1B).

###### 

Click here for additional data file.

###### 

**Figure S2**. Examination of the expression of marker genes by immunohistochemistry in salivary‐SCC samples.

A, Hematoxylin and eosin staining of the corresponding section (original magnification ×400).

B, Immunohistochemical expression of MUC7 on salivary‐SCC (Case 2) (original magnification ×400). Positive staining for MUC7 was observed on the cell surface of salivary‐SCC. Sections were dewaxed in xylene and dehydrated in graded ethanols according to standard procedures. Antigen retrieval was performed by incubating sections immersed in 10 mM citric acid in a microwave oven at 100°C. The primary antibodies used were an anti‐human MUC7 antibody (1:200 dilution; anti‐MUC7 rabbit polyclonal, ab224342; Abcam MA, USA).The secondary antibody used were anti‐rabbit antibodies (EnVision+/HRP Reagent, Agilent, CA, USA). Expression was visualized 3‐Amino‐9‐ethylcarbazole (AEC+, Agilent, CA, USA).

###### 

Click here for additional data file.

###### 

**Table S1**. STR analysis

**Table S2**. Evaluation value

**Table S3**. Primers used for RT‐PCR

###### 

Click here for additional data file.
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